Wali Gautam, Sue Carolyn M, Mackay-Sim Alan
Department of Neurogenetics, Kolling Institute of Medical Research, The University of Sydney, Sydney, NSW 2065, Australia.
Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia.
Brain Sci. 2018 Jul 31;8(8):142. doi: 10.3390/brainsci8080142.
Hereditary spastic paraplegia is an inherited, progressive paralysis of the lower limbs first described by Adolph Strümpell in 1883 with a further detailed description of the disease by Maurice Lorrain in 1888. Today, more than 100 years after the first case of HSP was described, we still do not know how mutations in HSP genes lead to degeneration of the corticospinal motor neurons. This review describes how patient-derived stem cells contribute to understanding the disease mechanism at the cellular level and use this for discovery of potential new therapeutics, focusing on mutations, the most common cause of HSP.
遗传性痉挛性截瘫是一种遗传性、进行性下肢麻痹疾病,由阿道夫·施特吕姆佩尔于1883年首次描述,莫里斯·洛兰于1888年对该疾病进行了更详细的描述。如今,在首例遗传性痉挛性截瘫病例被描述100多年后,我们仍然不知道遗传性痉挛性截瘫基因中的突变是如何导致皮质脊髓运动神经元退化的。本综述描述了患者来源的干细胞如何有助于在细胞水平上理解疾病机制,并将其用于发现潜在的新疗法,重点关注遗传性痉挛性截瘫最常见的病因——突变。